“As we invest to scale production of our commercial biomaterial products to meet expected demand in the United States and the Middle East, we are prioritizing our most promising cell therapy product candidates and programs and are rebalancing our workforce and identifying targeted expense reductions to support these priorities,” said CEO Robert J. Hariri.
“2023’s NYF Health Executive Jury are recognized for their exceptional reputation and world-renowned award-winning work,” said Scott Rose, President, New York Festivals Advertising Awards Competitions.
The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies.
The FDA approved Merck’s Keytruda for the treatment of stage IB, II or IIIA non-small cell lung cancer after resection or platinum-based chemotherapy.
The companies announced today that the EU approval is indicated for treating children as young as 6 months old with severe atopic dermatitis.
As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Fulling will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.